Slaying senescent cells

With a whopper of a B round and a new publication demonstrating both a causal role of senescent cells in atherosclerosis, and a therapeutic effect of eliminating them, Unity Biotechnology Inc. is readying to push three senolytic programs into the clinic.

The lead program will be in osteoarthritis (OA) of the knee, followed by programs in ophthalmic diseases including glaucoma and age-related macular degeneration (AMD), because those diseases have more straightforward development and regulatory paths than atherosclerosis does...